Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Chimerix, a biotechnology company developing orally-available antiviral therapeutics, has appointed Timothy King as vice president of clinical operations and Herve Mommeja-Marin as vice president of clinical research.
Subscribe to our email newsletter
Mr King is expected to look after clinical operations and site management for Chimerix and Dr Mommeja-Marin will oversee clinical strategy and study design. Both will report to Wendy Painter, chief medical officer of the company.
Most recently, Mr King has served as a group director at Quintiles, where he had responsibility for more than 20 Phase I to IV trials in over 40 countries for a wide range of drugs, biologics, devices and diagnostics, while Dr Mommeja-Marin was the senior medical director of infectious diseases in i3 Research.
Kenneth Moch, president and CEO of Chimerix, said: “Tim King and Herve Mommeja-Marin bring to Chimerix a wealth of talent and knowledge within infectious diseases which will be of great value as we advance of our antiviral clinical development programs.
“We anticipate significant progress in our two clinical stage programs – CMX001 against double-stranded DNA viruses and CMX157 against HIV – and look forward to working with Tim and Herve as we develop these assets.”